The NM_000152.5:c.868A>G variant in GAA is predicted to result in the substitution of asparagine by aspartate at amino acid 290 (p.Asn290Asp). It has been identified in six individuals by newborn screening, none with clinical features consistent with Pompe disease (PMID: 32064362, 37414610; Essawi et al. 2021, Egypt J Med Hum Genet 22:87). Four of these individuals are homozygous for the variant and have African ancestry (PMID: 37414610), and two patients are compound heterozygous for the variant and a variant that has been classified as pathogenic by the ClinGen Lysosomal Diseases VCEP, either c.2105G>A (p.Arg702His), phase unconfirmed, (ClinVar Variation ID: 426278, SCV004809068.1) (PMID: 32064362) or c.2238G>C (p.Trp746Cys) (ClinVar Variation ID: 265160, SCV002032122.1). In the latter, patient, the variants were confirmed to be in trans, and the father, who was described as "completely normal" but with reduced GAA activity, is homozygous for c.868A>G (p.Asn290Asp). Additional cases have been reported (PMID: 22644586, 33073007) but the second variant and clinical details were not provided. Due to the lack of evidence for clinical symptoms in the patients with this variant, PP4 and PM3 were not applied. The highest population minor allele frequency in gnomAD v2.1.1. is 0.00004 (1/24356, no homozygotes) in the African population, which is lower than the ClinGen Lysosomal Diseases VCEP's threshold (<0.001) for PM2_Supporting, meeting this criterion (PM2_Supporting). When expressed in COS cells, this variant was classified as Class E ("presumably nonpathogenic") by Kroos et al, 2012 (PMID:22644586). This includes 71% GAA activity in cells and 38% in medium, with synthesis and processing on Western blot (BS3_Supporting). The computational predictor REVEL gives a score of 0.561 which is neither above nor below the thresholds predicting a damaging (>0.7) or benign (<0.5) impact on GAA function. There is a ClinVar entry for this variant (Variation ID: 498117). In summary, this variant meets the criteria to be classified as a variant of uncertain significance for Pompe disease. The classification was first approved by the ClinGen Lysosomal Diseases Variant Curation Expert Panel on October 21, 2022. Since then, the data for this variant have been re-evaluated and new data have been included but the classification remains the same. The classification of variant of uncertain significance was reapproved on April 16, 2024. GAA-specific ACMG/AMP criteria met, as specified by the ClinGen Lysosomal Diseases Variant Curation Expert Panel (Specifications Version 2.0): PM2_Supporting, BS3_Supporting.